Yeah that’s a good point. Our trial design seems a lot smarter. The other thing which I keep coming back to is the eligibility criteria for starting uPCR. DMX has shown in our previous trials to have a more significant reduction on patients with higher starting uPCR. And obviously a higher reduction in uPCR leads to more improvement to kidney function and reduction of eGFR slope. So this all bodes well for us hopefully.
Note - a big disclaimer here for anyone that read my earlier posts - but I think for some reason I referred to uPCR as “uPVC”. Not sure if this was auto spell correct or if I’m dyslexic! But please just substitute these terms when reading….hopefully everyone knew what I meant.
Yeah that’s a good point. Our trial design seems a lot smarter....
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
32.0¢ |
Change
-0.015(4.48%) |
Mkt cap ! $175.8M | |||
| Open | High | Low | Value | Volume |
| 33.0¢ | 33.5¢ | 31.5¢ | $1.333M | 4.143M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 727594 | 32.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 32.5¢ | 170412 | 4 |
View Market Depth
| Last trade - 16.10pm 26/04/2024 (20 minute delay) ? |
|
|||||
|
Last
32.0¢ |
Change
-0.015 ( 3.15 %) |
||||
| Open | High | Low | Volume | ||
| 33.5¢ | 33.5¢ | 31.5¢ | 2261030 | ||
| Last updated 15.51pm 26/04/2024 ? | |||||
| DXB (ASX) Chart |